ASX Quarterly Health Wrap: Regulatory wins, clinical progress and strategic growth
The ASX healthcare sector rose in June, with the sector up 13.31% and up 2.27% in July, though still down about 18% year to date. Singular Health (SHG) reported US$500,000 licence payment and $10.1m cash, Imagion (IBX) received US FDA IND clearance for MagSense HER2 Phase 1b/2, and Recce (RCE) gained ethics approval to advance R327G to Phase 3.





